FindTrial
Sign In

Ischemia modified albumin (IMA) is associated with peripheral arterial disease and dialysis modality in chronic hemodialysis patients

Ischemia modified albumin (IMA) is associated with peripheral arterial disease and dialysis modality in chronic hemodialysis patients

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
TCTR
Registry ID
TCTR20200306001
Enrollment
Unknown
Registered
2020-03-06
Start date
2016-04-01
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

chronic hemodialysis patients chronic hemodialysis patients

Interventions

chronic hemodialysis patients
Screening

Sponsors

Ramathibodi hospital, Mahidol university
Lead Sponsor
University College London
Collaborator

Eligibility

Sex/Gender
All
Age
18 Years to 90 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria included receipt of chronic HD treatments for >2 weeks, age > 15 years and ability to provide valid informed consent. Patients who declined to participate in the study were excluded

Exclusion criteria

Exclusion criteria: Patients who declined to participate in the study were excluded.

Design outcomes

Primary

MeasureTime frame
Ankle-Brachial Index during study period ABI was measured using the vascular screening system (VaSera VS-2000, Fukuda Denshi, Japan)—

Secondary

MeasureTime frame
ischemia modified albumin during study period colorimetric method following reduction by dithiothreitol (DTT)—

Countries

Thailand

Contacts

Public ContactArkom Nongnuch

Ramathibodi hospital, Mahidol university

oatega@yahoo.com02-201-1400

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026